This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
Bevacizumab (an anti-vascular endothelial growth factor monoclonal antibody) was added to chemotherapy (carboplatin plus paclitaxel) and compared with chemotherapy alone (carboplatin and paclitaxel) alone. Six cycles of carboplatin (area under the curve=6) and paclitaxel 200mg/m 2 were given intravenously every three weeks with the same regimen plus bevacizumab (15mg/kg). If patients did not experience disease progression or intolerable toxicity, they received maintenance bevacizumab treatment every three weeks. Infusion times were five hours with bevacizumab and four hours with usual chemotherapy.
Location/setting
USA/Secondary care
Methods

Analytical approach:
A Markov model was developed to synthesise evidence from published studies, epidemiological data and one key clinical trial (the ECOG 4599 trial, Ramalingam, et al. 2008 , see 'Other Publications of Related Interest' for bibliographic details). The model time horizon was four years. The authors stated a US health care payer perspective was adopted.
Effectiveness data:
The key clinical outcome was overall survival; this was based on results from the ECOG (Eastern Cooperative Oncology) 4599 trial. Other end-points were progression-free survival, response rates and toxicity. The ECOG 4599 was a phase III randomised controlled trial (RCT) with 850 participants. The median follow-up was 19 months; an intention-to-treat analysis was undertaken. The trial showed a median two-month survival benefit for bevacizumab.
Monetary benefit and utility valuations:
Utility estimates were taken from two published reports of utilities for the health states (stable disease on therapy; stable disease off therapy; fever and neutropenia; severe bleeding; and progressive disease) in the model (Doyle, et al. 2008, and Nafees, et al. 2008 , see 'Other Publications of Related Interest' for bibliographic details).
